FDA OK's Cubist's Sivextro; another antibiotic 'GAIN'

After the markets closed on 20 June, the FDA gave the good news to Cubist Pharmaceuticals that its antibiotic Sivextro (tedizolid phosphate) gained the agency's approval as a treatment for acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-resistant (MRSA) and methicillin-susceptible strains, various Streptococcus species and Enterococcus faecalis.